Mylan Pharmaceuticals Inc
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Mylan Pharmaceuticals Inc
- Company name
- Mylan Pharmaceuticals Inc
- Organisation type
- Industry
- Registered legal name
- Mylan Pharmaceuticals Inc.
- Registry sponsor category
- Industry
- Legal Entity Identifier (LEI)
- 894500ZQWJQXJPI6B828
Related records
Parent companies (1)
- Viatris Inc. Direct and ultimate parent
Trials (165)
- A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
- A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers
- Applesauce Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg
- Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System
- Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System
- Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System With Askina Derm Overlay
- Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg
- Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg
- Comparative Bioavailability Study of Baclofen 20 mg Tablets in Healthy Male Volunteers / Fasting State
- Comparative Bioavailability Study of Clarithromycin 250 mg Tablets
- Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fasting State
- Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fed State
- Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
- Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch
- Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System
- Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day
- Extension Study of MYL-1701P-3001 for Safety and Efficacy
- Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg
- Fasting BE Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg
- Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg